Skip to main content


Johnson & Johnson is committed to the Sustainable Development Goals

Johnson & Johnson is committed to the Sustainable Development Goals

“By working collectively, the global health community can increase and accelerate the potential to achieve major research breakthroughs for the millions of people worldwide who suffer from devastating diseases like TB, malaria and NTD’s.”

Wim Parys

head of R&D at Johnson & Johnson Global Public Health

After the completion of the Millennium Goals in 2015, the members of the United Nations have set a new spot on the horizon: 2030, it still seems far future. The goal? Ending poverty, winning the fight against inequality and tackling climate change. Three big ambitions, poured into 17 interconnected goals: the Sustainable Development Goals or SDGs.


17 goals to transform our world

The Millennium Goals were primarily the domain of governments. To achieve the even higher ambitions of the SDGs, the UN calls on all global citizens to take action. This includes us, the employees of Johnson & Johnson. As a globally operating company we take our responsibility and contribute in different areas. Johnson & Johnson focuses on SDG’s 3, 5 and 17. SDG 3 covers “Good Health and Well Being”, and aims at a healthy life and wellbeing for everyone of all ages. This big goal is at the heart of our company. SDG 5 aims at achieving gender equality, a cornerstone within Johnson & Johnson. SDG 17 is all about partnerships. The SDG’s are too big for one organization, that’s why we face these challenges together with our worldwide partners. In the coming period, we will highlight through social media and the website how Johnson & Johnson contributes to achieving the various SDGs, starting with SDG3.


SDG3: good health for everyone

Working towards a healthy future for everyone is firmly anchored in our mission and vision. This is also at the heart of SDG3. Despite remarkable progress concerning global health, we face several big challenges:


  • Almost half a million people developed a drug-resistant form of tuberculosis (TB) in 2015 1

  • Globally, 36.7 million people were infected with HIV by the end of 2015 2

  • Nearly 400 million people are infected with the Dengue virus each year 3


SDG3 aspires to end these epidemics. In order to achieve this, R&D investments are needed aimed at diseases that primarily affect developing countries. Next to that, SDG3 focuses on universal access to effective medicines and training of competent healthcare professionals in developing areas.


Global Public Health

To contribute to solving these challenges, Johnson & Johnson, the parent company of Janssen, started the Global Public Health program. The vision for Johnson & Johnson Global Public Health is linked to a deep belief that the world needs new tools specifically developed and targeted to address infectious disease threats and help the most vulnerable in the world. We therefore implement new business models to sustainably get our medical innovations there where they are needed the most. We do this together with likeminded partners. Read more about the Johnson & Johnson Global Public Health program here.